At some point, one has to wonder who really benefits from the artificial intelligence revolution. Take jobs, for example. AI ...
In February 2026, Sarepta Therapeutics announced that New Zealand’s Medsafe approved its clinical trial application for INSIGHTT, a first-in-human Phase 1 study of SRP-1005, an investigational siRNA ...